Blueprint Medicines Corp  

(Public, NASDAQ:BPMC)   Watch this stock  
Find more results for George D Albers
-1.32 (-4.41%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 28.00 - 32.81
52 week 18.00 - 32.81
Open 31.03
Vol / Avg. 691,894.00/723,427.00
Mkt cap 738.35M
P/E     -
Div/yield     -
EPS     -
Shares 25.83M
Beta     -
Inst. own 1%

Key stats and ratios

Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets - -149.04%
Return on average equity - -
Employees 60 -
CDP Score - -


215 1st St
CAMBRIDGE, MA 02142-1213
United States - Map
+1-617-3747580 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Blueprint Medicines Corporation (Blueprint) is a biopharmaceutical company. The Company is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. The Company developed a molecule drug pipeline in cancer and a genetic disease. Its lead drug candidate BLU-285 targets KIT Exon 17 and PDGFRa D842V, active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. The Company's BLU-285 is developed for patients with systemic mastocytosis (SM) and defined subsets of patients with gastrointestinal stromal tumor (GIST). The Company's Imatinib, which is an inhibitor of KIT and PDGFRa, is approved in SM and GIST. The Company's other drug candidate is BLU-554, which targets FGFR4, a kinase that is activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma. The Company is also developing a drug candidate to target both RET and RET resistant mutants.

Officers and directors

Daniel S. Lynch Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Jeffrey W Albers President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Anthony L Boral Senior Vice President - Clinical Development
Age: 52
Bio & Compensation  - Reuters
Christoph Lengauer Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Kyle D Kuvalanka Chief Business Officer
Age: 46
Bio & Compensation  - Reuters
Alexis Borisy Director
Age: 43
Bio & Compensation  - Reuters
Stephen C. Knight M.D. Director
Age: 55
Bio & Compensation  - Reuters
Nicholas Lydon Director
Age: 58
Bio & Compensation  - Reuters
Thilo Schroeder Ph.D. Director
Age: 33
Bio & Compensation  - Reuters
George D Demetri Independent Director
Age: 58
Bio & Compensation  - Reuters